UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Charles Bancroft
|
|||
|
b)
|
Position/status
|
Senior Independent Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Release of 17,446 notional ADSs from the GSK Non-Executive Director
Share Allocation Arrangements following the termination of those
arrangements, the withholding of 1,602 notional ADSs for tax and
the final release of 15,843 ADSs representing the balance. These
ADSs will be held by Charles Bancroft until he retires from the
Board. A residual cash payment of $32.60 will be paid to Charles
Bancroft.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$38.805
|
15,843
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2025-03-25
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Anne Beal
|
|||
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|||
|
c)
|
Initial notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature of the transaction
|
Release of 1,988 notional ADSs from the GSK Non-Executive Director
Share Allocation Arrangements following the termination of those
arrangements, the withholding of 1,018 notional ADSs for tax and
the final release of 970 ADSs representing the balance. These
shares will be held by Dr Anne Beal until she retires from the
Board. A residual cash payment of $4.66 will be paid to Dr Anne
Beal.
|
|||
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$38.805
|
970
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume
Price
|
|
||||
|
e)
|
Date of the transaction
|
2025-03-25
|
|||
|
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Hal Dietz
|
|||
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|||
|
c)
|
Initial notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature of the transaction
|
Release of 1,760 notional ADSs from the GSK Non-Executive Director
Share Allocation Arrangements following the termination of those
arrangements, the withholding of 909 notional ADSs for tax and the
final release of 850 ADSs representing the balance. These shares
will be held by Dr Hal Dietz until he retires from the Board. A
residual cash payment of $38.42 will be paid to Dr Hal
Dietz.
|
|||
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$38.805
|
850
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume
Price
|
|
||||
|
e)
|
Date of the transaction
|
2025-03-25
|
|||
|
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Jesse Goodman
|
|||
|
b)
|
Position/status
|
Independent Non-Executive Director
|
|||
|
c)
|
Initial notification/amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature of the transaction
|
Release of 13,924 notional ADSs from the GSK Non-Executive Director
Share Allocation Arrangements following the termination of those
arrangements, the withholding of 7,082 notional ADSs for tax and
the final release of 6,842 ADSs representing the balance. These
shares will be held by Dr Jesse Goodman until he retires from the
Board. A residual cash payment of $11.64 will be paid to Dr Jesse
Goodman.
|
|||
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$38.805
|
6,842
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume
Price
|
|
||||
|
e)
|
Date of the transaction
|
2025-03-25
|
|||
|
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
28, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|